1 / 3

Lipid-Nanoparticle-Based Genomic Medicines Market Size, Share, Forecast 2032 - iSay Research

Lipid-Nanoparticle-Based Genomic Medicines Market is projected to reach USD 36.50 Billion by 2032 with CAGR of 8.40%

Download Presentation

Lipid-Nanoparticle-Based Genomic Medicines Market Size, Share, Forecast 2032 - iSay Research

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Market Overview/Outlook (2022 to 2032) The global market for Lipid-Nanoparticle-Based Genomic Medicines is expected to grow between 2023 and 2032 due to effective drug delivery, advancements in genomic medicine, rising incidence of genetic disorders, precision medicine, and personalized therapies. Global Lipid-Nanoparticle-Based Genomic Medicines Market Drivers Effective Drug Delivery: Target cells can receive genomic medicines, such as RNA-based therapeutics, efficiently through the use of lipid nanoparticles as carriers. They improve these medications' stability and bioavailability, which makes it easier for them to be effectively delivered to particular tissues. Get Report Sample @ https://isayresearch.com/sample/2302 Global Lipid-Nanoparticle Based Genomic Medicines Market – Merger and Acquisitions •Alexion, AstraZeneca Rare Disease to Acquire LogicBio Therapeutics to Accelerate Growth in Genomic Medicine (2022) Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, Mass.-based LogicBio Therapeutics, Inc., a pioneering genomic medicine company. The proposed acquisition aims to rapidly accelerate Alexion’s growth in genomic medicines through LogicBio’s unique technology, experienced rare disease R&D team, and expertise in pre-clinical development. Challenges Impacting the Global Lipid-Nanoparticle-Based Genomic Medicines Market Safety Issue: Notwithstanding developments in lipid nanoparticle formulations, a general acceptance of these delivery systems may be impeded by worries about long-term safety and possible adverse effects. For market participants, addressing safety concerns and guaranteeing regulatory compliance are crucial tasks. Enquiry Before Buying @ https://isayresearch.com/buying-request/2302 List of Prominent Players:

  2. •Moderna Inc. •Pfizer Inc. •BioNTech SE •Arbutus Biopharma Corporation •Arrowhead Pharmaceuticals Inc. •CureVac N.V. •Lipocalyx •Acuitas Therapeutics •Precision NanoSystems Inc. •IONTAS Limited •Genevant Sciences •Roche Holding AG •Alnylam Pharmaceuticals Inc. •SiO2 Materials Science •Ethris GmbH •Others Read Full Report @ https://isayresearch.com/report/2302/lipid-nanoparticle-based-genomic- medicines-market/ Segmentation of Global Lipid-Nanoparticle-Based Genomic Medicines Market: By Type: •Liposome-based Nanoparticles •Micelle-based Nanoparticles •Lipid-coated Nanoparticles By Application: •Cancer Treatments •Infectious Diseases •Genetic Disorders •Cardiovascular Diseases •Others By Therapeutic Payload: •mRNA-based Therapeutics •siRNA-based Therapeutics •miRNA-based Therapeutics

  3. By End-User: •Hospitals •Biopharmaceuticals Companies •Research Institutes By Region: •North America (U.S., Canada, Mexico) •Europe (Germany, France, UK, Italy, Spain, Rest of Europe) •Asia Pacific (China, Japan, India, Southeast Asia, Rest of APAC) •Latin America (Brazil, Argentina, Rest of Latin America) •Middle East & Africa (GCC Countries, UAE, Rest of MEA) Regional Analysis: •North America: United States: The United States boasts an extremely sophisticated healthcare system, complete with a well-established regulatory framework that makes it easier to develop, test, and commercialize cutting-edge medical technologies such as lipid nanoparticles for genomic medicine. The United States is home to a large number of top biotechnology and pharmaceutical companies that specialize in drug delivery technologies and genomic medicine. These major players in the industry support market expansion by conducting research and developing new products. Clinical trials and regulatory approvals in the biotechnology and pharmaceutical industries are centered in the United States. Read More About: https://www.linkedin.com/pulse/global-lipid-nanoparticle-based-genomic-medicines-market-vasa- 6w90c/ https://www.linkedin.com/pulse/march%25C3%25A9-des-m%25C3%25A9dicaments- g%25C3%25A9nomiques-%25C3%25A0-base-de-2024-taille-huggins-6pq7c/ https://www.linkedin.com/pulse/detaillierte-umfrage-und-berichtsausblick-zum-globalen-justin-s- gswtc/

More Related